Cellectis Publishes A 'Molecular Therapy' Article On A SMART DUAL CAR T-Cell Approach For Treating Recalcitrant Solid Tumors
Portfolio Pulse from Benzinga Newsdesk
Cellectis has published a study in 'Molecular Therapy' showcasing their TALEN®-mediated gene editing for SMART DUAL CAR T-cells, targeting resistant solid tumors. This advancement could enhance the efficacy of CAR T-cell therapies in treating solid tumors.
August 26, 2024 | 8:34 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cellectis has demonstrated a new approach using TALEN®-mediated gene editing for SMART DUAL CAR T-cells, potentially improving treatment for solid tumors. This could enhance the company's position in the biotech sector.
The publication of this research highlights Cellectis' innovative approach in the biotech field, specifically targeting a challenging area in cancer treatment. This could lead to increased investor interest and potential stock price appreciation.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100